newsfilter
← Latest News
GlobeNewswire·

Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights

Topline Phase 2b data now expected in the second quarter of 2024 for the IMPAHCT global Phase 2b/Phase 3 clinical trial of AV-101 for pulmonary arterial hypertension (PAH)More than 100 sites activated in 20 countries